fibaworldcupasiaqualifiers2023| Baiji Shenzhou BTK inhibitor Baiyueze approved for follicular lymphoma indication in China

Baekje Shenzhou announced on May 13fibaworldcupasiaqualifiers2023, its BTK inhibitor Baiyuze ® (zebutinib) has been conditionally approved for registration by the State Food and Drug Administration of China (SDA), with the following new indications: in combination with otuzumab, it is suitable for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least second-line systemic treatment.

Tags:

Prev: playtoearnspace| Alibaba rose nearly 4% before the market and announced results tomorrow
Next: roulettemachinecasino| Langbo Technology (603655.SH): It plans to spend 5 million yuan to 8 million yuan to buy back shares